Provider: NIHR Journals Library
Content:text/plain; charset="UTF-8"
TY  - JOUR
LB  - 1.
AU  - Abraham, C
AU  - Cho, JH
TI  - Inflammatory bowel disease
J2  - N Engl J Med
PY  - 2009
VL  - 361
SP  - 2066
EP  - 2078
UR  - https://doi.org/10.1056/NEJMra0804647
ER  - 
TY  - JOUR
LB  - 2.
AU  - Hendrickson, BA
AU  - Gokhale, R
AU  - Cho, JH
TI  - Clinical aspects and pathophysiology of inflammatory bowel disease
J2  - Clin Microbiol Rev
PY  - 2002
VL  - 15
SP  - 79
EP  - 94
UR  - https://doi.org/10.1128/CMR.15.1.79-94.2002
ER  - 
TY  - JOUR
LB  - 3.
AU  - Park, JH
AU  - Peyrin-Biroulet, L
AU  - Eisenhut, M
AU  - Shin, JI
TI  - IBD immunopathogenesis: a comprehensive review of inflammatory molecules
J2  - Autoimmun Rev
PY  - 2017
VL  - 16
SP  - 416
EP  - 426
UR  - https://doi.org/10.1016/j.autrev.2017.02.013
ER  - 
TY  - GEN
LB  - 4.
AU  - Crohn’s and Colitis UK
TI  - Crohn’s Disease
CY  - Hatfield
PB  - Crohn’s and Colitis UK
PY  - 2019
UR  - www.crohnsandcolitis.org.uk/about-inflammatory-bowel-disease/crohns-disease
Y2  - 24 July 2019
ER  - 
TY  - ELEC
LB  - 5.
AU  - Johns Hopkins Medicine
TI  - Crohn’s Disease: Introduction
PY  - 2001
UR  - www.hopkinsmedicine.org/gastroenterology_hepatology/_pdfs/small_large_intestine/crohns_disease.pdf
M1  - 5 August 2019
ER  - 
TY  - JOUR
LB  - 6.
AU  - Cosnes, J
AU  - Gower-Rousseau, C
AU  - Seksik, P
AU  - Cortot, A
TI  - Epidemiology and natural history of inflammatory bowel diseases
J2  - Gastroenterology
PY  - 2011
VL  - 140
SP  - 1785
EP  - 1794
UR  - https://doi.org/10.1053/j.gastro.2011.01.055
ER  - 
TY  - GEN
LB  - 7.
AU  - York Teaching Hospital
TI  - Crohn’s Disease
CY  - York
PB  - York Teaching Hospital
PY  - 2019
UR  - www.yorkhospitals.nhs.uk/our-services/a-z-of-services/inflammatory-bowel-disease-at-york-hospital/crohns-disease/
Y2  - 24 July 2019
ER  - 
TY  - JOUR
LB  - 8.
AU  - Ananthakrishnan, AN
TI  - Environmental triggers for inflammatory bowel disease
J2  - Curr Gastroenterol Rep
PY  - 2013
VL  - 15
SP  - 302
UR  - https://doi.org/10.1007/s11894-012-0302-4
ER  - 
TY  - JOUR
LB  - 9.
AU  - Feagins, LA
AU  - Iqbal, R
AU  - Spechler, SJ
TI  - Case-control study of factors that trigger inflammatory bowel disease flares
J2  - World J Gastroenterol
PY  - 2014
VL  - 20
SP  - 4329
EP  - 4334
UR  - https://doi.org/10.3748/wjg.v20.i15.4329
ER  - 
TY  - JOUR
LB  - 10.
AU  - Wang, L
AU  - Wang, F-S
AU  - Gershwin, ME
TI  - Human autoimmune diseases: a comprehensive update
J2  - J Intern Med
PY  - 2015
VL  - 278
SP  - 369
EP  - 395
UR  - https://doi.org/10.1111/joim.12395
ER  - 
TY  - JOUR
LB  - 11.
AU  - Langholz, E
TI  - Current trends in inflammatory bowel disease: the natural history
J2  - Therap Adv Gastroenterol
PY  - 2010
VL  - 3
SP  - 77
EP  - 86
UR  - https://doi.org/10.1177/1756283X10361304
ER  - 
TY  - JOUR
LB  - 12.
AU  - Loftus, EV, Jr
AU  - Schoenfeld, P
AU  - Sandborn, WJ
TI  - The epidemiology and natural history of Crohn’s disease in population-based patient cohorts from North America: a systematic review
J2  - Aliment Pharmacol Ther
PY  - 2002
VL  - 16
SP  - 51
EP  - 60
UR  - https://doi.org/10.1046/j.1365-2036.2002.01140.x
ER  - 
TY  - JOUR
LB  - 13.
AU  - Munkholm, P
AU  - Langholz, E
AU  - Davidsen, M
AU  - Binder, V
TI  - Disease activity courses in a regional cohort of Crohn’s disease patients
J2  - Scand J Gastroenterol
PY  - 1995
VL  - 30
SP  - 699
EP  - 706
UR  - https://doi.org/10.3109/00365529509096316
ER  - 
TY  - JOUR
LB  - 14.
AU  - Lapidus, A
AU  - Bernell, O
AU  - Hellers, G
AU  - Löfberg, R
TI  - Clinical course of colorectal Crohn’s disease: a 35-year follow-up study of 507 patients
J2  - Gastroenterology
PY  - 1998
VL  - 114
SP  - 1151
EP  - 1160
UR  - https://doi.org/10.1016/S0016-5085(98)70420-2
ER  - 
TY  - ELEC
LB  - 15.
AU  - Regueiro, M
AU  - Hashash, JA
TI  - Overview of the Medical Management of Mild (Low Risk) Crohn Disease in Adults
PY  - 2018
UR  - www.uptodate.com/contents/overview-of-the-medical-management-of-mild-low-risk-crohn-disease-in-adults
M1  - 18 April 2019
ER  - 
TY  - JOUR
LB  - 16.
AU  - Gomollón, F
AU  - Dignass, A
AU  - Annese, V
AU  - Tilg, H
AU  - Van Assche, G
AU  - Lindsay, JO
TI  - 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: diagnosis and medical management
J2  - J Crohns Colitis
PY  - 2017
VL  - 11
SP  - 3
EP  - 25
UR  - https://doi.org/10.1093/ecco-jcc/jjw168
ER  - 
TY  - JOUR
LB  - 17.
AU  - Duricova, D
AU  - Burisch, J
AU  - Jess, T
AU  - Gower-Rousseau, C
AU  - Lakatos, PL
AU  - ECCO-EpiCom
TI  - Age-related differences in presentation and course of inflammatory bowel disease: an update on the population-based literature
J2  - J Crohns Colitis
PY  - 2014
VL  - 8
SP  - 1351
EP  - 1361
UR  - https://doi.org/10.1016/j.crohns.2014.05.006
ER  - 
TY  - JOUR
LB  - 18.
AU  - Hovde Ø, Moum BA
TI  - Epidemiology and clinical course of Crohn’s disease: results from observational studies
J2  - World J Gastroenterol
PY  - 2012
VL  - 18
SP  - 1723
EP  - 1731
UR  - https://doi.org/10.3748/wjg.v18.i15.1723
ER  - 
TY  - JOUR
LB  - 19.
AU  - García Rodríguez, LA
AU  - González-Pérez, A
AU  - Johansson, S
AU  - Wallander, MA
TI  - Risk factors for inflammatory bowel disease in the general population
J2  - Aliment Pharmacol Ther
PY  - 2005
VL  - 22
SP  - 309
EP  - 315
UR  - https://doi.org/10.1111/j.1365-2036.2005.02564.x
ER  - 
TY  - JOUR
LB  - 20.
AU  - Rubin, GP
AU  - Hungin, AP
AU  - Kelly, PJ
AU  - Ling, J
TI  - Inflammatory bowel disease: epidemiology and management in an English general practice population
J2  - Aliment Pharmacol Ther
PY  - 2000
VL  - 14
SP  - 1553
EP  - 1559
UR  - https://doi.org/10.1046/j.1365-2036.2000.00886.x
ER  - 
TY  - JOUR
LB  - 21.
AU  - Floyd, DN
AU  - Langham, S
AU  - Séverac, HC
AU  - Levesque, BG
TI  - The economic and quality-of-life burden of Crohn’s disease in Europe and the United States, 2000 to 2013: a systematic review
J2  - Dig Dis Sci
PY  - 2015
VL  - 60
SP  - 299
EP  - 312
UR  - https://doi.org/10.1007/s10620-014-3368-z
ER  - 
TY  - JOUR
LB  - 22.
AU  - Ghosh, N
AU  - Premchand, P
TI  - A UK cost of care model for inflammatory bowel disease
J2  - Frontline Gastroenterol
PY  - 2015
VL  - 6
SP  - 169
EP  - 174
UR  - https://doi.org/10.1136/flgastro-2014-100514
ER  - 
TY  - JOUR
LB  - 23.
AU  - Shivananda, S
AU  - Hordijk, ML
AU  - Pena, AS
AU  - Mayberry, JF
TI  - Crohn’s disease: risk of recurrence and reoperation in a defined population
J2  - Gut
PY  - 1989
VL  - 30
SP  - 990
EP  - 995
UR  - https://doi.org/10.1136/gut.30.7.990
ER  - 
TY  - JOUR
LB  - 24.
AU  - Maaser, C
AU  - Sturm, A
AU  - Vavricka, SR
AU  - Kucharzik, T
AU  - Fiorino, G
AU  - Annese, V
TI  - ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications
J2  - J Crohns Colitis
PY  - 2019
VL  - 13
SP  - 144
EP  - 164
UR  - https://doi.org/10.1093/ecco-jcc/jjy113
ER  - 
TY  - JOUR
LB  - 25.
AU  - Sturm, A
AU  - Maaser, C
AU  - Calabrese, E
AU  - Annese, V
AU  - Fiorino, G
AU  - Kucharzik, T
TI  - ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects
J2  - J Crohns Colitis
PY  - 2019
VL  - 13
SP  - 273
EP  - 284
UR  - https://doi.org/10.1093/ecco-jcc/jjy114
ER  - 
TY  - JOUR
LB  - 26.
AU  - Peyrin-Biroulet, L
AU  - Panés, J
AU  - Sandborn, WJ
AU  - Vermeire, S
AU  - Danese, S
AU  - Feagan, BG
TI  - Defining disease severity in inflammatory bowel diseases: current and future directions
J2  - Clin Gastroenterol Hepatol
PY  - 2016
VL  - 14
SP  - 348
EP  - 54.e17
UR  - https://doi.org/10.1016/j.cgh.2015.06.001
ER  - 
TY  - JOUR
LB  - 27.
AU  - Walmsley, RS
AU  - Ayres, RC
AU  - Pounder, RE
AU  - Allan, RN
TI  - A simple clinical colitis activity index
J2  - Gut
PY  - 1998
VL  - 43
SP  - 29
EP  - 32
UR  - https://doi.org/10.1136/gut.43.1.29
ER  - 
TY  - JOUR
LB  - 28.
AU  - Harvey, RF
AU  - Bradshaw, JM
TI  - A simple index of Crohn’s-disease activity
J2  - Lancet
PY  - 1980
VL  - 1
SP  - 514
UR  - https://doi.org/10.1016/S0140-6736(80)92767-1
ER  - 
TY  - JOUR
LB  - 29.
AU  - Vermeire, S
AU  - Schreiber, S
AU  - Sandborn, WJ
AU  - Dubois, C
AU  - Rutgeerts, P
TI  - Correlation between the Crohn’s disease activity and Harvey-Bradshaw indices in assessing Crohn’s disease severity
J2  - Clin Gastroenterol Hepatol
PY  - 2010
VL  - 8
SP  - 357
EP  - 363
UR  - https://doi.org/10.1016/j.cgh.2010.01.001
ER  - 
TY  - JOUR
LB  - 30.
AU  - Iskandar, HN
AU  - Ciorba, MA
TI  - Biomarkers in inflammatory bowel disease: current practices and recent advances
J2  - Transl Res
PY  - 2012
VL  - 159
SP  - 313
EP  - 325
UR  - https://doi.org/10.1016/j.trsl.2012.01.001
ER  - 
TY  - ELEC
LB  - 31.
AU  - National Institute for Health and Care Excellence (NICE)
TI  - Crohn’s Disease: Management
PY  - 2019
UR  - www.nice.org.uk/guidance/ng129/chapter/Recommendations#inducing-remission-in-crohns-disease
M1  - 5 August 2019
ER  - 
TY  - JOUR
LB  - 32.
AU  - Rogler, G
TI  - Top-down or step-up treatment in Crohn’s disease?
J2  - Dig Dis
PY  - 2013
VL  - 31
SP  - 83
EP  - 90
UR  - https://doi.org/10.1159/000347190
ER  - 
TY  - JOUR
LB  - 33.
AU  - Tsui, JJ
AU  - Huynh, HQ
TI  - Is top-down therapy a more effective alternative to conventional step-up therapy for Crohn’s disease?
J2  - Ann Gastroenterol
PY  - 2018
VL  - 31
SP  - 413
EP  - 424
ER  - 
TY  - JOUR
LB  - 34.
AU  - Sparrow, MP
AU  - Melmed, GY
AU  - Devlin, S
AU  - Kozuch, P
AU  - Raffals, L
AU  - Loftus, EV, Jr
TI  - De-escalating medical therapy in Crohn’s disease patients who are in deep remission: a RAND appropriateness panel
J2  - GastroHep
PY  - 2019
VL  - 1
SP  - 108
EP  - 117
UR  - https://doi.org/10.1002/ygh2.337
ER  - 
TY  - JOUR
LB  - 35.
AU  - D’Haens, G
AU  - Baert, F
AU  - van Assche, G
AU  - Caenepeel, P
AU  - Vergauwe, P
AU  - Tuynman, H
TI  - Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial
J2  - Lancet
PY  - 2008
VL  - 371
SP  - 660
EP  - 667
UR  - https://doi.org/10.1016/S0140-6736(08)60304-9
ER  - 
TY  - JOUR
LB  - 36.
AU  - Fan, R
AU  - Zhong, J
AU  - Wang, ZT
AU  - Li, SY
AU  - Zhou, J
AU  - Tang, YH
TI  - Evaluation of ‘top-down’ treatment of early Crohn’s disease by double balloon enteroscopy
J2  - World J Gastroenterol
PY  - 2014
VL  - 20
SP  - 14479
EP  - 14487
UR  - https://doi.org/10.3748/wjg.v20.i39.14479
ER  - 
TY  - JOUR
LB  - 37.
AU  - Khanna, R
AU  - Bressler, B
AU  - Levesque, BG
AU  - Zou, G
AU  - Stitt, LW
AU  - Greenberg, GR
TI  - Early combined immunosuppression for the management of Crohn’s disease (REACT): a cluster randomised controlled trial
J2  - Lancet
PY  - 2015
VL  - 386
SP  - 1825
EP  - 1834
UR  - https://doi.org/10.1016/S0140-6736(15)00068-9
ER  - 
TY  - JOUR
LB  - 38.
AU  - Kaul, A
AU  - Hutfless, S
AU  - Liu, L
AU  - Bayless, TM
AU  - Marohn, MR
AU  - Li, X
TI  - Serum anti-glycan antibody biomarkers for inflammatory bowel disease diagnosis and progression: a systematic review and meta-analysis
J2  - Inflamm Bowel Dis
PY  - 2012
VL  - 18
SP  - 1872
EP  - 1884
UR  - https://doi.org/10.1002/ibd.22862
ER  - 
TY  - JOUR
LB  - 39.
AU  - Segal, AW
TI  - Making sense of the cause of Crohn’s – a new look at an old disease
J2  - F1000Res
PY  - 2016
VL  - 5
SP  - 2510
UR  - https://doi.org/10.12688/f1000research.9699.2
ER  - 
TY  - JOUR
LB  - 40.
AU  - Mitsuyama, K
AU  - Niwa, M
AU  - Takedatsu, H
AU  - Yamasaki, H
AU  - Kuwaki, K
AU  - Yoshioka, S
TI  - Antibody markers in the diagnosis of inflammatory bowel disease
J2  - World J Gastroenterol
PY  - 2016
VL  - 22
SP  - 1304
EP  - 1310
UR  - https://doi.org/10.3748/wjg.v22.i3.1304
ER  - 
TY  - JOUR
LB  - 41.
AU  - Kamm, F
AU  - Strauch, U
AU  - Degenhardt, F
AU  - Lopez, R
AU  - Kunst, C
AU  - Rogler, G
TI  - Serum anti-glycan-antibodies in relatives of patients with inflammatory bowel disease
J2  - PLOS ONE
PY  - 2018
VL  - 13
SP  - e0194222
UR  - https://doi.org/10.1371/journal.pone.0194222
ER  - 
TY  - ELEC
LB  - 42.
AU  - Glycominds
TI  - Crohn’s Disease: Prognostic Serological Marker Profile
PY  - 2016
UR  - http://ibdx.net/assets/img/flyers/cd_prognosis.pdf
M1  - 8 August 2019
ER  - 
TY  - ELEC
LB  - 43.
AU  - Glycominds
TI  - IBDX®ALCA IgG ELISA Kit.
PY  - 2019
UR  - www.ibdx.net/assets/img/product/alca_insert.pdf
M1  - 8 August 2019
ER  - 
TY  - JOUR
LB  - 44.
AU  - Papp, M
AU  - Foldi, I
AU  - Altorjay, I
AU  - Palyu, E
AU  - Udvardy, M
AU  - Tumpek, J
TI  - Anti-microbial antibodies in celiac disease: trick or treat?
J2  - World J Gastroenterol
PY  - 2009
VL  - 15
SP  - 3891
EP  - 3900
UR  - https://doi.org/10.3748/wjg.15.3891
ER  - 
TY  - JOUR
LB  - 45.
AU  - Román, AL
AU  - Muñoz, F
TI  - Comorbidity in inflammatory bowel disease
J2  - World J Gastroenterol
PY  - 2011
VL  - 17
SP  - 2723
EP  - 2733
UR  - https://doi.org/10.3748/wjg.v17.i22.2723
ER  - 
TY  - JOUR
LB  - 46.
AU  - Lee, JC
AU  - Lyons, PA
AU  - McKinney, EF
AU  - Sowerby, JM
AU  - Carr, EJ
AU  - Bredin, F
TI  - Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis
J2  - J Clin Invest
PY  - 2011
VL  - 121
SP  - 4170
EP  - 4179
UR  - https://doi.org/10.1172/JCI59255
ER  - 
TY  - JOUR
LB  - 47.
AU  - McKinney, EF
AU  - Lee, JC
AU  - Jayne, DR
AU  - Lyons, PA
AU  - Smith, KG
TI  - T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection
J2  - Nature
PY  - 2015
VL  - 523
SP  - 612
EP  - 616
UR  - https://doi.org/10.1038/nature14468
ER  - 
TY  - JOUR
LB  - 48.
AU  - McKinney, EF
AU  - Lyons, PA
AU  - Carr, EJ
AU  - Hollis, JL
AU  - Jayne, DR
AU  - Willcocks, LC
TI  - A CD8+ T cell transcription signature predicts prognosis in autoimmune disease
J2  - Nat Med
PY  - 2010
VL  - 16
SP  - 586
EP  - 591
UR  - https://doi.org/10.1038/nm.2130
ER  - 
TY  - JOUR
LB  - 49.
AU  - Yi, JS
AU  - Cox, MA
AU  - Zajac, AJ
TI  - T-cell exhaustion: characteristics, causes and conversion
J2  - Immunology
PY  - 2010
VL  - 129
SP  - 474
EP  - 481
UR  - https://doi.org/10.1111/j.1365-2567.2010.03255.x
ER  - 
TY  - JOUR
LB  - 50.
AU  - Biasci, D
AU  - Lee, JC
AU  - Noor, NM
AU  - Pombal, DR
AU  - Hou, M
AU  - Lewis, N
TI  - A blood-based prognostic biomarker in IBD
J2  - Gut
PY  - 2019
VL  - 68
SP  - 1386
EP  - 1395
UR  - https://doi.org/10.1136/gutjnl-2019-318343
ER  - 
TY  - JOUR
LB  - 51.
AU  - Parkes, M
AU  - Noor, NM
AU  - Dowling, F
AU  - Leung, H
AU  - Bond, S
AU  - Whitehead, L
TI  - PRedicting Outcomes For Crohn’s dIsease using a moLecular biomarkEr (PROFILE): protocol for a multicentre, randomised, biomarker-stratified trial
J2  - BMJ Open
PY  - 2018
VL  - 8
SP  - e026767
UR  - https://doi.org/10.1136/bmjopen-2018-026767
ER  - 
TY  - ELEC
LB  - 52.
AU  - National Institute for Health and Care Excellence (NICE)
TI  - PredictSURE-IBD and IBDX to Guide Personalised Treatment of Crohn’s Disease. Final Scope
PY  - 2019
UR  - www.nice.org.uk/guidance/gid-dg10029/documents/final-scope
M1  - 6 September 2019
ER  - 
TY  - ELEC
LB  - 53.
AU  - Glycominds
TI  - Non-Invasive Solutions to Gastrointestinal Diseases Detection
PY  - 2019
UR  - www.glycominds.com/
M1  - 20 August 2019
ER  - 
TY  - ELEC
LB  - 54.
AU  - PredictImmune
TI  - PredictImmune
PY  - 2019
UR  - www.predictimmune.com/
M1  - 20 August 2019
ER  - 
TY  - ELEC
LB  - 55.
AU  - Barton, S
AU  - Edwards, SJ
AU  - Bacelar, M
AU  - Karner, C
AU  - Cain, P
TI  - PredictSURE-IBD and IBDX to Guide Personalised Treatment of Crohn’s Disease in Adults
PY  - 2019
UR  - www.crd.york.ac.uk/prospero/display_record.php?RecordID=138737
M1  - 20 August 2019
ER  - 
TY  - GEN
LB  - 56.
AU  - Centre for Reviews and Dissemination
TI  - Systematic Reviews: CRD’s Guidance for Undertaking Reviews in Healthcare
CY  - York
PB  - CRD, University of York
PY  - 2009
UR  - www.york.ac.uk/media/crd/Systematic_Reviews.pdf
Y2  - 20 August 2019
ER  - 
TY  - ELEC
LB  - 57.
AU  - National Institute for Health and Care Excellence (NICE)
TI  - Diagnostics Assessment Programme Manual
PY  - 2011
UR  - www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-diagnostics-guidance/Diagnostics-assessment-programme-manual.pdf
M1  - 20 August 2019
ER  - 
TY  - ELEC
LB  - 58.
AU  - Cochrane Methods
TI  - Screening and Diagnostic Tests. Handbook for DTA Reviews
PY  - 2018
UR  - https://methods.cochrane.org/sdt/handbook-dta-reviews
M1  - 20 August 2019
ER  - 
TY  - JOUR
LB  - 59.
AU  - Hayden, JA
AU  - Côté, P
AU  - Bombardier, C
TI  - Evaluation of the quality of prognosis studies in systematic reviews
J2  - Ann Intern Med
PY  - 2006
VL  - 144
SP  - 427
EP  - 437
UR  - https://doi.org/10.7326/0003-4819-144-6-200603210-00010
ER  - 
TY  - JOUR
LB  - 60.
AU  - Hayden, JA
AU  - van der Windt, DA
AU  - Cartwright, JL
AU  - Côté, P
AU  - Bombardier, C
TI  - Assessing bias in studies of prognostic factors
J2  - Ann Intern Med
PY  - 2013
VL  - 158
SP  - 280
EP  - 286
UR  - https://doi.org/10.7326/0003-4819-158-4-201302190-00009
ER  - 
TY  - JOUR
LB  - 61.
AU  - Moons, KGM
AU  - Wolff, RF
AU  - Riley, RD
AU  - Whiting, PF
AU  - Westwood, M
AU  - Collins, GS
TI  - PROBAST: a tool to assess risk of bias and applicability of prediction model studies: explanation and elaboration
J2  - Ann Intern Med
PY  - 2019
VL  - 170
SP  - W1
EP  - W33
UR  - https://doi.org/10.7326/M18-1377
ER  - 
TY  - JOUR
LB  - 62.
AU  - Wolff, RF
AU  - Moons, KGM
AU  - Riley, RD
AU  - Whiting, PF
AU  - Westwood, M
AU  - Collins, GS
TI  - PROBAST: a tool to assess the risk of bias and applicability of prediction model studies
J2  - Ann Intern Med
PY  - 2019
VL  - 170
SP  - 51
EP  - 58
UR  - https://doi.org/10.7326/M18-1376
ER  - 
TY  - DATA
LB  - 63.
AU  - Higgins, J
AU  - Green, S
TI  - Cochrane Handbook for Systematic Reviews of Interventions
Version 5.1.0PY  - 2011
UR  - http://handbook-5-1.cochrane.org/
Y2  - 18 April 2019
ER  - 
TY  - JOUR
LB  - 64.
AU  - Sterne, JA
AU  - Hernán, MA
AU  - Reeves, BC
AU  - Savović, J
AU  - Berkman, ND
AU  - Viswanathan, M
TI  - ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
J2  - BMJ
PY  - 2016
VL  - 355
SP  - i4919
UR  - https://doi.org/10.1136/bmj.i4919
ER  - 
TY  - ELEC
LB  - 65.
AU  - Critical Appraisal Skills Programme
TI  - CASP Checklist: 10 Questions to Help You Make Sense of a Qualitative Research
PY  - 2018
UR  - https://casp-uk.net/wp-content/uploads/2018/01/CASP-Qualitative-Checklist-2018.pdf
M1  - 9 December 2020
ER  - 
TY  - JOUR
LB  - 66.
AU  - Bonneau, J
AU  - Dumestre-Perard, C
AU  - Rinaudo-Gaujous, M
AU  - Genin, C
AU  - Sparrow, M
AU  - Roblin, X
AU  - Paul, S
TI  - Systematic review: new serological markers (anti-glycan, anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes
J2  - Autoimmun Rev
PY  - 2015
VL  - 14
SP  - 231
EP  - 245
UR  - https://doi.org/10.1016/j.autrev.2014.11.004
ER  - 
TY  - JOUR
LB  - 67.
AU  - Harrell, L
AU  - Weyer, G
AU  - Yarden, J
AU  - Dotan, N
AU  - Hanauer, S
TI  - T1289. Anti-glycan antibodies are associated with disabling disease course and complicated disease behavior in patients with Crohn’s disease
J2  - Gastroenterology
PY  - 2010
VL  - 138
SP  - S-529
UR  - https://doi.org/10.1016/S0016-5085(10)62443-2
ER  - 
TY  - JOUR
LB  - 68.
AU  - Kaul, A
AU  - Hutfless, S
AU  - Liu, L
AU  - Bayless, TM
AU  - Marohn, MR
AU  - Li, X
TI  - Serum anti-glycan antibody biomarkers for inflammatory bowel disease diagnosis and progression: a meta-analysis
J2  - Gastroenterology
PY  - 2011
VL  - 5
SP  - S152
UR  - https://doi.org/10.1016/S0016-5085(11)60619-7
ER  - 
TY  - JOUR
LB  - 69.
AU  - Paul, S
AU  - Boschetti, G
AU  - Rinaudo-Gaujous, M
AU  - Moreau, A
AU  - Del Tedesco, E
AU  - Bonneau, J
TI  - Association of anti-glycan antibodies and inflammatory bowel disease course
J2  - J Crohns Colitis
PY  - 2015
VL  - 9
SP  - 445
EP  - 451
UR  - https://doi.org/10.1093/ecco-jcc/jjv063
ER  - 
TY  - JOUR
LB  - 70.
AU  - Prideaux, L
AU  - De Cruz, P
AU  - Ng, SC
AU  - Kamm, MA
TI  - Serological antibodies in inflammatory bowel disease: a systematic review
J2  - Inflamm Bowel Dis
PY  - 2012
VL  - 18
SP  - 1340
EP  - 1355
UR  - https://doi.org/10.1002/ibd.21903
ER  - 
TY  - JOUR
LB  - 71.
AU  - Rieder, F
AU  - Hahn, P
AU  - Finsterhoelzl, L
AU  - Dirmeier, A
AU  - Cai, H
AU  - Shen, B
TI  - Serum anti-glycan antibodies can contribute to differential diagnosis and disease stratification of pediatric Crohn’s disease patients
J2  - Gastroenterology
PY  - 2010
VL  - 138
SP  - S301
EP  - S302
UR  - https://doi.org/10.1016/S0016-5085(10)61387-X
ER  - 
TY  - JOUR
LB  - 72.
AU  - Rieder, F
AU  - Hahn, P
AU  - Finsterhoelzl, L
AU  - Schleder, S
AU  - Wolf, A
AU  - Dirmeier, A
TI  - Clinical utility of anti-glycan antibodies in pediatric Crohn’s disease in comparison with an adult cohort
J2  - Inflamm Bowel Dis
PY  - 2012
VL  - 18
SP  - 1221
EP  - 1231
UR  - https://doi.org/10.1002/ibd.21854
ER  - 
TY  - JOUR
LB  - 73.
AU  - Rieder, F
AU  - Hahn, P
AU  - Finsterholzl, L
AU  - Dirmeier, A
AU  - Shen, B
AU  - Rogler, G
TI  - Clinical utility of anti-glycan antibodies in pediatric Crohn’s disease in comparison with an adult cohort
J2  - J Crohn’s Colitis
PY  - 2011
VL  - 5
SP  - S48
ER  - 
TY  - JOUR
LB  - 74.
AU  - Rieder, F
AU  - Lopez, R
AU  - Franke, A
AU  - Wolf, A
AU  - Schleder, S
AU  - Dirmeier, A
TI  - Characterization of changes in serum anti-glycan antibodies in Crohn’s disease – a longitudinal analysis
J2  - PLOS ONE
PY  - 2011
VL  - 6
SP  - e18172
UR  - https://doi.org/10.1371/journal.pone.0018172
ER  - 
TY  - JOUR
LB  - 75.
AU  - Rieder, F
AU  - Schleder, S
AU  - Wolf, A
AU  - Dirmeier, A
AU  - Strauch, U
AU  - Obermeier, F
TI  - Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with complicated Crohn’s disease behavior
J2  - Inflamm Bowel Dis
PY  - 2010
VL  - 16
SP  - 263
EP  - 274
UR  - https://doi.org/10.1002/ibd.21046
ER  - 
TY  - JOUR
LB  - 76.
AU  - Rieder, F
AU  - Schleder, S
AU  - Wolf, A
AU  - Dirmeier, A
AU  - Strauch, U
AU  - Obermeier, F
TI  - Serum anti-glycan antibodies predict complicated Crohn’s disease behavior: a cohort study
J2  - Inflamm Bowel Dis
PY  - 2010
VL  - 16
SP  - 1367
EP  - 1375
UR  - https://doi.org/10.1002/ibd.21179
ER  - 
TY  - JOUR
LB  - 77.
AU  - Rieder, F
AU  - Schleder, S
AU  - Wolf, A
AU  - Schirbel, A
AU  - Franke, A
AU  - Dirmeier, A
TI  - Characterization of changes of serum anti-glycan antibodies in individual patients over time in inflammatory bowel disease (IBD)
J2  - Gastroenterology
PY  - 2010
VL  - 138
SP  - S522
UR  - https://doi.org/10.1016/S0016-5085(10)62412-2
ER  - 
TY  - JOUR
LB  - 78.
AU  - Seow, CH
AU  - Stempak, JM
AU  - Xu, W
AU  - Lan, H
AU  - Griffiths, AM
AU  - Greenberg, GR
TI  - Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype
J2  - Am J Gastroenterol
PY  - 2009
VL  - 104
SP  - 1426
EP  - 1434
UR  - https://doi.org/10.1038/ajg.2009.79
ER  - 
TY  - JOUR
LB  - 79.
AU  - Wolfel, G
AU  - Lopez, R
AU  - Hosl, J
AU  - Kunst, C
AU  - Martina, M
AU  - Rieder, F
TI  - The anti-glycan antibodies amca and alca are associated with shorter time to surgical recurrence in Crohn’s disease (CD)
J2  - Gastroenterology
PY  - 2017
VL  - 152
SP  - S605
UR  - https://doi.org/10.1016/S0016-5085(17)32158-3
ER  - 
TY  - JOUR
LB  - 80.
AU  - Halder, SL
AU  - Stempak, JM
AU  - Sharaf, A
AU  - Xu, W
AU  - Greenberg, GR
AU  - Steinhart, H
TI  - Biomarkers associated with progressive behaviour in Crohn’s disease
J2  - Gastroenterology
PY  - 2010
VL  - 138
UR  - https://doi.org/10.1016/S0016-5085(10)60173-4
ER  - 
TY  - ELEC
LB  - 81.
AU  - International Standard Randomised Controlled Trials Number Registry
TI  - PROFILE – Personalised Medicine in Crohn’s Disease
PY  - 2019
UR  - www.isrctn.com/ISRCTN11808228
M1  - 9 October 2019
ER  - 
TY  - ELEC
LB  - 82.
AU  - ClinicalTrials.gov
TI  - The PRECIOUS Study: Predicting Crohn’s & ColitIs Outcomes in the United States
PY  - 2019
UR  - https://clinicaltrials.gov/ct2/show/NCT03952364
M1  - 2 September 2019
ER  - 
TY  - JOUR
LB  - 83.
AU  - Lyons, P
AU  - Noor, N
AU  - Lee, JC
AU  - McKinney, EF
AU  - Parkes, M
AU  - Smith, KGC
TI  - P256 Anti-glycan antibody seropositivity at diagnosis does not predict future disease course in patients with Crohn's disease
J2  - J Crohns Colitis
PY  - 2020
VL  - 14
IS  - Suppl. 1
SP  - S278
UR  - https://doi.org/10.1093/ecco-jcc/jjz203.385
ER  - 
TY  - JOUR
LB  - 84.
AU  - Smids, C
AU  - Horjus Talabur Horje, CS
AU  - Drylewicz, J
AU  - Roosenboom, B
AU  - Groenen, MJM
AU  - van Koolwijk, E
TI  - Intestinal T cell profiling in inflammatory bowel disease: linking T cell subsets to disease activity and disease course
J2  - J Crohns Colitis
PY  - 2018
VL  - 12
SP  - 465
EP  - 475
UR  - https://doi.org/10.1093/ecco-jcc/jjx160
ER  - 
TY  - ELEC
LB  - 85.
AU  - Canadian Agency for Drugs and Technologies in Health
TI  - Strings Attached: CADTH's Database Search Filters
UR  - https://cadth.ca/resources/finding-evidence/strings-attached-cadths-database-search-filters#eco
M1  - January 2019
ER  - 
TY  - JOUR
LB  - 86.
AU  - Arber, M
AU  - Garcia, S
AU  - Veale, T
AU  - Edwards, M
AU  - Shaw, A
AU  - Glanville, JM
TI  - Performance of Ovid MEDLINE search filters to identify health state utility studies
J2  - Int J Technol Assess Health Care
PY  - 2017
VL  - 33
SP  - 472
EP  - 480
UR  - https://doi.org/10.1017/S0266462317000897
ER  - 
TY  - BOOK
LB  - 87.
AU  - Drummond, M
AU  - Sculpher, MJ
AU  - Claxton, K
AU  - Stoddart, GL
AU  - Torrance, GW
TI  - Methods for the Economic Evaluation of Health Care Programmes
ET  - 2
CY  - Oxford
PB  - Oxford University Press
PY  - 1997
ER  - 
TY  - JOUR
LB  - 88.
AU  - Marchetti, M
AU  - Liberato, NL
AU  - Di Sabatino, A
AU  - Corazza, GR
TI  - Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn’s disease
J2  - Eur J Health Econ
PY  - 2013
VL  - 14
SP  - 853
EP  - 861
UR  - https://doi.org/10.1007/s10198-012-0430-7
ER  - 
TY  - JOUR
LB  - 89.
AU  - Dretzke, J
AU  - Edliln, R
AU  - Round, J
AU  - Connock, M
AU  - Hulme, C
AU  - Czeczot, J
TI  - A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for Crohn’s disease
J2  - Health Technol Assess
PY  - 2011
VL  - 15
IS  - 6
UR  - https://doi.org/10.3310/hta15060
ER  - 
TY  - JOUR
LB  - 90.
AU  - Rafia, R
AU  - Scope, A
AU  - Harnan, S
AU  - Stevens, JW
AU  - Stevenson, M
AU  - Lobo, A
TI  - Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy: an evidence review group perspective of a NICE single technology appraisal
J2  - PharmacoEconomics
PY  - 2016
VL  - 34
SP  - 1241
EP  - 1253
UR  - https://doi.org/10.1007/s40273-016-0436-6
ER  - 
TY  - JOUR
LB  - 91.
AU  - Hodgson, R
AU  - Walton, M
AU  - Biswas, M
AU  - Mebrahtu, T
AU  - Woolacott, N
TI  - Ustekinumab for treating moderately to severely active Crohn’s disease after prior therapy: an Evidence Review Group perspective of a NICE single technology appraisal
J2  - PharmacoEconomics
PY  - 2018
VL  - 36
SP  - 387
EP  - 398
UR  - https://doi.org/10.1007/s40273-017-0593-2
ER  - 
TY  - ELEC
LB  - 92.
AU  - National Institute for Health and Care Excellence (NICE)
TI  - Therapeutic Monitoring of TNF-alpha Inhibitors in Crohn’s Disease (LISA-TRACKER ELISA Kits, IDKmonitor ELISA Kits, and Promonitor ELISA Kits)
UR  - www.nice.org.uk/guidance/dg22
M1  - January 2019
ER  - 
TY  - JOUR
LB  - 93.
AU  - Bodger, K
AU  - Kikuchi, T
AU  - Hughes, D
TI  - Cost-effectiveness of biological therapy for Crohn’s disease: Markov cohort analyses incorporating United Kingdom patient-level cost data
J2  - Aliment Pharmacol Ther
PY  - 2009
VL  - 30
SP  - 265
EP  - 274
UR  - https://doi.org/10.1111/j.1365-2036.2009.04033.x
ER  - 
TY  - JOUR
LB  - 94.
AU  - Saito, S
AU  - Shimizu, U
AU  - Nan, Z
AU  - Mandai, N
AU  - Yokoyama, J
AU  - Terajima, K
AU  - Akazawa, K
TI  - Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn’s disease: a cost-effectiveness analysis
J2  - J Crohns Colitis
PY  - 2013
VL  - 7
SP  - 167
EP  - 174
UR  - https://doi.org/10.1016/j.crohns.2012.04.007
ER  - 
TY  - JOUR
LB  - 95.
AU  - Mayberry, JF
AU  - Lobo, A
AU  - Ford, AC
AU  - Thomas, A
TI  - NICE clinical guideline (CG152): the management of Crohn’s disease in adults, children and young people
J2  - Aliment Pharmacol Therapeutics
PY  - 2013
VL  - 37
SP  - 195
EP  - 203
UR  - https://doi.org/10.1111/apt.12102
ER  - 
TY  - JOUR
LB  - 96.
AU  - Freeman, K
AU  - Connock, M
AU  - Auguste, P
AU  - Taylor-Phillips, S
AU  - Mistry, H
AU  - Shyangdan, D
TI  - Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER®enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor®ELISA kits] versus standard care in patients with Crohn’s disease: systematic reviews and economic modelling
J2  - Health Technol Assess
PY  - 2016
VL  - 20
IS  - 83
UR  - https://doi.org/10.3310/hta20830
ER  - 
TY  - JOUR
LB  - 97.
AU  - Loftus, EV, Jr
AU  - Johnson, SJ
AU  - Yu, AP
AU  - Wu, EQ
AU  - Chao, J
AU  - Mulani, PM
TI  - Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn’s disease
J2  - Eur J Gastroenterol Hepatol
PY  - 2009
VL  - 21
SP  - 1302
EP  - 1309
UR  - https://doi.org/10.1097/MEG.0b013e32832a8d71
ER  - 
TY  - JOUR
LB  - 98.
AU  - Lindsay, J
AU  - Punekar, YS
AU  - Morris, J
AU  - Chung-Faye, G
TI  - Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn’s disease – modelling outcomes in active luminal and fistulizing disease in adults
J2  - Aliment Pharmacol Ther
PY  - 2008
VL  - 28
SP  - 76
EP  - 87
UR  - https://doi.org/10.1111/j.1365-2036.2008.03709.x
ER  - 
TY  - JOUR
LB  - 99.
AU  - Clark, W
AU  - Raftery, J
AU  - Song, F
AU  - Barton, P
AU  - Cummins, C
AU  - Fry-Smith, A
TI  - Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn’s disease
J2  - Health Technol Assess
PY  - 2003
VL  - 7
IS  - 3
UR  - https://doi.org/10.3310/hta7030
ER  - 
TY  - JOUR
LB  - 100.
AU  - Benedini, V
AU  - Caporaso, N
AU  - Corazza, GR
AU  - Rossi, Z
AU  - Fornaciari, G
AU  - Cottone, M
TI  - Burden of Crohn’s disease: economics and quality of life aspects in Italy
J2  - Clinicoecon Outcomes Res
PY  - 2012
VL  - 4
SP  - 209
EP  - 218
UR  - https://doi.org/10.2147/CEOR.S31114
ER  - 
TY  - JOUR
LB  - 101.
AU  - Mozzi, A
AU  - Meregaglia, M
AU  - Lazzaro, C
AU  - Tornatore, V
AU  - Belfiglio, M
AU  - Fattore, G
TI  - A comparison of EuroQol 5-Dimension health-related utilities using Italian, UK, and US preference weights in a patient sample
J2  - Clinicoecon Outcomes Res
PY  - 2016
VL  - 8
SP  - 267
EP  - 274
UR  - https://doi.org/10.2147/CEOR.S98226
ER  - 
TY  - JOUR
LB  - 102.
AU  - Stark, RG
AU  - Reitmeir, P
AU  - Leidl, R
AU  - König, HH
TI  - Validity, reliability, and responsiveness of the EQ-5D in inflammatory bowel disease in Germany
J2  - Inflamm Bowel Dis
PY  - 2010
VL  - 16
SP  - 42
EP  - 51
UR  - https://doi.org/10.1002/ibd.20989
ER  - 
TY  - JOUR
LB  - 103.
AU  - Rencz, F
AU  - Lakatos, PL
AU  - Gulacsi, L
AU  - Brodszky, V
AU  - Kurti, Z
AU  - Lovas, S
TI  - Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn’s disease
J2  - Qual Life Res
PY  - 2019
VL  - 28
SP  - 141
EP  - 152
UR  - https://doi.org/10.1007/s11136-018-2003-4
ER  - 
TY  - BOOK
LB  - 104.
AU  - Dolan, P
AU  - Gudex, C
AU  - Kind, P
AU  - Williams, A
TI  - A Social Tariff for EuroQol: Results from a UK General Population Survey. Discussion Paper 138
CY  - York
PB  - Centre of Health Economics, University of York
PY  - 1995
ER  - 
TY  - JOUR
LB  - 105.
AU  - Badia, X
AU  - Roset, M
AU  - Herdman, M
AU  - Kind, P
TI  - A comparison of United Kingdom and Spanish general population time trade-off values for EQ-5D health states
J2  - Med Decis Making
PY  - 2001
VL  - 21
SP  - 7
EP  - 16
UR  - https://doi.org/10.1177/0272989X0102100102
ER  - 
TY  - JOUR
LB  - 106.
AU  - Dolan, P
AU  - Gudex, C
AU  - Kind, P
AU  - Williams, A
TI  - The time trade-off method: results from a general population study
J2  - Health Econ
PY  - 1996
VL  - 5
SP  - 141
EP  - 154
UR  - https://doi.org/10.1002/(SICI)1099-1050(199603)5:2<141::AID-HEC189>3.0.CO;2-N
ER  - 
TY  - JOUR
LB  - 107.
AU  - Dolan, P
TI  - Modeling valuations for EuroQol health states
J2  - Med Care
PY  - 1997
VL  - 35
SP  - 1095
EP  - 1108
UR  - https://doi.org/10.1097/00005650-199711000-00002
ER  - 
TY  - JOUR
LB  - 108.
AU  - Badia, X
AU  - Roset, M
AU  - Montserrat, S
AU  - Herdman, M
AU  - Segura, A
TI  - The Spanish version of EuroQol: a description and its applications. European Quality of Life scale
J2  - Med Clin
PY  - 1999
VL  - 112
IS  - Suppl. 1
SP  - 79
EP  - 85
ER  - 
TY  - JOUR
LB  - 109.
AU  - Casellas, F
AU  - Vivancos, JL
AU  - Sampedro, M
AU  - Malagelada, JR
TI  - Relevance of the phenotypic characteristics of Crohn’s disease in patient perception of health-related quality of life
J2  - Am J Gastroenterol
PY  - 2005
VL  - 100
SP  - 2737
EP  - 2742
UR  - https://doi.org/10.1111/j.1572-0241.2005.00360.x
ER  - 
TY  - JOUR
LB  - 110.
AU  - Casellas, F
AU  - Rodrigo, L
AU  - Niño, P
AU  - Pantiga, C
AU  - Riestra, S
AU  - Malagelada, JR
TI  - Sustained improvement of health-related quality of life in Crohn’s disease patients treated with infliximab and azathioprine for 4 years
J2  - Inflamm Bowel Dis
PY  - 2007
VL  - 13
SP  - 1395
EP  - 1400
UR  - https://doi.org/10.1002/ibd.20205
ER  - 
TY  - JOUR
LB  - 111.
AU  - Huamán, JW
AU  - Casellas, F
AU  - Borruel, N
AU  - Peláez, A
AU  - Torrejón, A
AU  - Castells, I
TI  - Cutoff values of the Inflammatory Bowel Disease Questionnaire to predict a normal health related quality of life
J2  - J Crohns Colitis
PY  - 2010
VL  - 4
SP  - 637
EP  - 641
UR  - https://doi.org/10.1016/j.crohns.2010.07.006
ER  - 
TY  - EDBOOK
LB  - 112.
AU  - Rue, M
AU  - Badia, X
TI  - The Spanish EuroQol Tariff: Results from the Catalan Health Survey based on Self-rated Health
AU  - Badia, X
AU  - Herdman, M
AU  - Segura, A
TI  - EuroQol, Plenary Meeting
CY  - Barcelona
PB  - Institut Universitari de Salut Publiea de Catalunya
PY  - 1996
SP  - 77
EP  - 98
ER  - 
TY  - JOUR
LB  - 113.
AU  - Casellas, F
AU  - López-Vivancos, J
AU  - Badia, X
AU  - Vilaseca, J
AU  - Malagelada, JR
TI  - Impact of surgery for Crohn’s disease on health-related quality of life
J2  - Am J Gastroenterol
PY  - 2000
VL  - 95
SP  - 177
EP  - 182
UR  - https://doi.org/10.1111/j.1572-0241.2000.01681.x
ER  - 
TY  - JOUR
LB  - 114.
AU  - Casellas, F
AU  - Arenas, JI
AU  - Baudet, JS
AU  - Fábregas, S
AU  - García, N
AU  - Gelabert, J
TI  - Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study
J2  - Inflamm Bowel Dis
PY  - 2005
VL  - 11
SP  - 488
EP  - 496
UR  - https://doi.org/10.1097/01.MIB.0000159661.55028.56
ER  - 
TY  - JOUR
LB  - 115.
AU  - Saro, C
AU  - Ceballos, D
AU  - Muñoz, F
AU  - de la Coba, C
AU  - Aguilar, MD
AU  - Lázaro, P
TI  - Clinical status, quality of life, and work productivity in Crohn’s disease patients after one year of treatment with adalimumab
J2  - Rev Esp Enferm Dig
PY  - 2017
VL  - 109
SP  - 122
EP  - 129
UR  - https://doi.org/10.17235/reed.2016.4600/2016
ER  - 
TY  - JOUR
LB  - 116.
AU  - Holko, P
AU  - Kawalec, P
AU  - Mossakowska, M
AU  - Pilc, A
TI  - Health-related quality of life impairment and indirect cost of Crohn’s disease: a self-report study in Poland
J2  - PLOS ONE
PY  - 2016
VL  - 11
SP  - e0168586
UR  - https://doi.org/10.1371/journal.pone.0168586
ER  - 
TY  - JOUR
LB  - 117.
AU  - Golicki, D
AU  - Jakubczyk, M
AU  - Niewada, M
AU  - Wrona, W
AU  - Busschbach, JJ
TI  - Valuation of EQ-5D health states in Poland: first TTO-based social value set in Central and Eastern Europe
J2  - Value Health
PY  - 2010
VL  - 13
SP  - 289
EP  - 297
UR  - https://doi.org/10.1111/j.1524-4733.2009.00596.x
ER  - 
TY  - JOUR
LB  - 118.
AU  - Devlin, NJ
AU  - Shah, KK
AU  - Feng, Y
AU  - Mulhern, B
AU  - van Hout, B
TI  - Valuing health-related quality of life: an EQ-5D-5L value set for England
J2  - Health Econ
PY  - 2018
VL  - 27
SP  - 7
EP  - 22
UR  - https://doi.org/10.1002/hec.3564
ER  - 
TY  - ELEC
LB  - 119.
AU  - National Institute for Health and Care Excellence (NICE)
TI  - Ustekinumab for Moderately to Severely Active Crohn’s Disease After Previous Treatment
PY  - 2017
UR  - www.nice.org.uk/guidance/ta456
M1  - July 2019
ER  - 
TY  - JOUR
LB  - 120.
AU  - Hoekman, D
AU  - Stibbe, J
AU  - Baert, F
AU  - Caenepeel, P
AU  - Vergauwe, P
AU  - De Vos, M
TI  - Long-term outcome of early combined immunosuppression versus conventional management in newly diagnosed Crohn’s disease
J2  - J Crohns Colitis
PY  - 2018
VL  - 12
SP  - 517
EP  - 524
UR  - https://doi.org/10.1093/ecco-jcc/jjy014
ER  - 
TY  - ELEC
LB  - 121.
AU  - Latimer, N
TI  - NICE DSU Technical Support Document 14. Undertaking Survival Analysis for Economic Evaluations Alongside Clinical Trials – Extrapolation with Patient-level Data
PY  - 2013
UR  - http://nicedsu.org.uk/wp-content/uploads/2016/03/NICE-DSU-TSD-Survival-analysis.updated-March-2013.v2.pdf
M1  - March 2021
ER  - 
TY  - JOUR
LB  - 122.
AU  - Guyot, P
AU  - Ades, AE
AU  - Ouwens, MJ
AU  - Welton, NJ
TI  - Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
J2  - BMC Med Res Methodol
PY  - 2012
VL  - 12
SP  - 9
UR  - https://doi.org/10.1186/1471-2288-12-9
ER  - 
TY  - JOUR
LB  - 123.
AU  - Tsui, JJ
AU  - Huynh, HQ
TI  - Is top-down therapy a more effective alternative to conventional step-up therapy for Crohn’s disease?
J2  - Ann Gastroenterol
PY  - 2018
VL  - 31
SP  - 413
EP  - 424
ER  - 
TY  - ELEC
LB  - 124.
AU  - National Institute for Health and Care Excellence (NICE)
TI  - British National Formulary
PY  - 2019
UR  - https://bnf.nice.org.uk/
M1  - 30 October 2019
ER  - 
TY  - ELEC
LB  - 125.
AU  - National Institute for Health and Care Excellence (NICE)
TI  - Vedolizumab for Treating Moderately to Severely Active Crohn’s Disease After Prior Therapy
PY  - 2015
UR  - www.nice.org.uk/guidance/ta352
M1  - July 2019
ER  - 
TY  - JOUR
LB  - 126.
AU  - Hanauer, SB
AU  - Sandborn, WJ
AU  - Rutgeerts, P
AU  - Fedorak, RN
AU  - Lukas, M
AU  - MacIntosh, D
TI  - Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial
J2  - Gastroenterology
PY  - 2006
VL  - 130
SP  - 323
EP  - 333
UR  - https://doi.org/10.1053/j.gastro.2005.11.030
ER  - 
TY  - JOUR
LB  - 127.
AU  - Watanabe, M
AU  - Hibi, T
AU  - Lomax, KG
AU  - Paulson, SK
AU  - Chao, J
AU  - Alam, MS
TI  - Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn’s disease
J2  - J Crohns Colitis
PY  - 2012
VL  - 6
SP  - 160
EP  - 173
UR  - https://doi.org/10.1016/j.crohns.2011.07.013
ER  - 
TY  - JOUR
LB  - 128.
AU  - Feagan, BG
AU  - Sandborn, WJ
AU  - Gasink, C
AU  - Jacobstein, D
AU  - Lang, Y
AU  - Friedman, JR
TI  - Ustekinumab as induction and maintenance therapy for Crohn’s disease
J2  - N Engl J Med
PY  - 2016
VL  - 375
SP  - 1946
EP  - 1960
UR  - https://doi.org/10.1056/NEJMoa1602773
ER  - 
TY  - JOUR
LB  - 129.
AU  - Sandborn, WJ
AU  - Feagan, BG
AU  - Rutgeerts, P
AU  - Hanauer, S
AU  - Colombel, JF
AU  - Sands, BE
TI  - Vedolizumab as induction and maintenance therapy for Crohn’s disease
J2  - N Engl J Med
PY  - 2013
VL  - 369
SP  - 711
EP  - 721
UR  - https://doi.org/10.1056/NEJMoa1215739
ER  - 
TY  - JOUR
LB  - 130.
AU  - Sandborn, WJ
AU  - Gasink, C
AU  - Gao, LL
AU  - Blank, MA
AU  - Johanns, J
AU  - Guzzo, C
TI  - Ustekinumab induction and maintenance therapy in refractory Crohn’s disease
J2  - N Engl J Med
PY  - 2012
VL  - 367
SP  - 1519
EP  - 1528
UR  - https://doi.org/10.1056/NEJMoa1203572
ER  - 
TY  - JOUR
LB  - 131.
AU  - Sands, BE
AU  - Feagan, BG
AU  - Rutgeerts, P
AU  - Colombel, JF
AU  - Sandborn, WJ
AU  - Sy, R
TI  - Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed
J2  - Gastroenterology
PY  - 2014
VL  - 147
SP  - 618
EP  - 27.e3
UR  - https://doi.org/10.1053/j.gastro.2014.05.008
ER  - 
TY  - JOUR
LB  - 132.
AU  - Hanauer, SB
AU  - Feagan, BG
AU  - Lichtenstein, GR
AU  - Mayer, LF
AU  - Schreiber, S
AU  - Colombel, JF
TI  - Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial
J2  - Lancet
PY  - 2002
VL  - 359
SP  - 1541
EP  - 1549
UR  - https://doi.org/10.1016/S0140-6736(02)08512-4
ER  - 
TY  - ELEC
LB  - 133.
AU  - Office for National Statistics
TI  - National Life Tables: England and Wales. 2015–17
UR  - www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/nationallifetablesenglandandwalesreferencetables
M1  - October 2019
ER  - 
TY  - JOUR
LB  - 134.
AU  - Silverstein, MD
AU  - Loftus, EV
AU  - Sandborn, WJ
AU  - Tremaine, WJ
AU  - Feagan, BG
AU  - Nietert, PJ
TI  - Clinical course and costs of care for Crohn’s disease: Markov model analysis of a population-based cohort
J2  - Gastroenterology
PY  - 1999
VL  - 117
SP  - 49
EP  - 57
UR  - https://doi.org/10.1016/S0016-5085(99)70549-4
ER  - 
TY  - JOUR
LB  - 135.
AU  - Ara, R
AU  - Brazier, JE
TI  - Populating an economic model with health state utility values: moving toward better practice
J2  - Value Health
PY  - 2010
VL  - 13
SP  - 509
EP  - 518
UR  - https://doi.org/10.1111/j.1524-4733.2010.00700.x
ER  - 
TY  - ELEC
LB  - 136.
AU  - Office for National Statistics
TI  - Consumer Price Inflation Index for Medical Services (DKC3)
PY  - 2018
UR  - www.ons.gov.uk/economy/inflationandpriceindices/timeseries/dkc3/mm23
M1  - 12 December 2018
ER  - 
TY  - ELEC
LB  - 137.
AU  - Department of Health and Social Care (NHS Improvement)
TI  - NHS National Schedule of Reference Costs 2017 to 2018
UR  - https://improvement.nhs.uk/resources/reference-costs/
M1  - November 2019
ER  - 
TY  - BOOK
LB  - 138.
AU  - Curtis, L
AU  - Burns, A
TI  - Unit Costs of Health and Social Care 2018
CY  - Canterbury
PB  - Personal Social Services Research Unit, University of Kent
PY  - 2018
UR  - www.pssru.ac.uk/project-pages/unit-costs/unit-costs-2018
Y2  - November 2019
ER  - 
TY  - RPRT
LB  - 139.
AU  - Wailoo, A
AU  - Tosh, J
TI  - Use of Tumour Necrosis Factor Alpha (TNF a) Inhibitors (Adalimumab and Infliximab) for Crohn’s Disease: Report by the Decision Support Unit
CY  - London
PB  - NICE
PY  - 2009
ER  - 
TY  - JOUR
LB  - 140.
AU  - Martin, AD
AU  - Quinn, KM
AU  - Park, JH
TI  - MCMCpack: Markov Chain Monte Carlo in R
J2  - J Stat Software
PY  - 2011
VL  - 42
SP  - 1
EP  - 21
UR  - https://doi.org/10.18637/jss.v042.i09
ER  - 
TY  - BOOK
LB  - 141.
AU  - Venables, WN
AU  - Ripley, BD
TI  - Modern Applied Statistics with S
ET  - 4th
CY  - New York, NY
PB  - Springer
PY  - 2002
UR  - https://doi.org/10.1007/978-0-387-21706-2
ER  - 
TY  - ELEC
LB  - 142.
AU  - National Institute for Health and Care Excellence (NICE)
TI  - Guide to the Methods of Technology Appraisal 2013
PY  - 2013
UR  - www.nice.org.uk/process/pmg9/chapter/foreword
M1  - 18 December 2018
ER  - 
TY  - JOUR
LB  - 143.
AU  - Baert, FJ
AU  - Moortgat, L
AU  - Van Assche, GA
AU  - Caenepeel, P
AU  - Vergauwe, PL
AU  - De Vos, M
TI  - Mucosal healing predicts sustained clinical remission in early Crohn’s disease
J2  - Gastroenterology
PY  - 2010
VL  - 138
SP  - 463
EP  - 468
UR  - https://doi.org/10.1053/j.gastro.2009.09.056
ER  - 
TY  - JOUR
LB  - 144.
AU  - Chau, NA
AU  - Romero, D
AU  - Toolsie, P
AU  - Jimmy, J
AU  - Bleidt, BA
TI  - Assessment of biological agents in the treatment regimen of moderate to severe Crohn’s disease
J2  - Pharmacotherapy
PY  - 2015
VL  - 35
SP  - e299
EP  - e300
ER  - 
TY  - JOUR
LB  - 145.
AU  - Colombel, JF
AU  - Ungaro, R
AU  - Aggarwal, S
AU  - Topaloglu, O
AU  - Skup, M
AU  - Lee, WJ
TI  - Efficacy and safety of early biologic treatment of Crohn’s disease in adult and paediatric patients: a systematic review
J2  - J Crohns Colitis
PY  - 2018
VL  - 12
SP  - S461
UR  - https://doi.org/10.1093/ecco-jcc/jjx180.819
ER  - 
TY  - JOUR
LB  - 146.
AU  - Hirschmann, S
AU  - Neurath, MF
TI  - Top-down approach to biological therapy of Crohn’s disease
J2  - Expert Opinion Biological Ther
PY  - 2017
VL  - 17
SP  - 285
EP  - 293
UR  - https://doi.org/10.1080/14712598.2017.1287170
ER  - 
TY  - JOUR
LB  - 147.
AU  - Hommes, DW
TI  - Step-up versus top-down therapy in the treatment of Crohn’s disease
J2  - Gastroenterol Hepatol
PY  - 2006
VL  - 2
SP  - 546
EP  - 547
ER  - 
TY  - BOOK
LB  - 148.
AU  - Hutfless, S
AU  - Lau, BD
AU  - Wilson, LM
AU  - Lazarev, M
AU  - Bass, EB
TI  - Pharmacological Management of Crohn’s Disease: Future Research Needs
CY  - Rockville, MD
PB  - Agency for Healthcare Research and Quality
PY  - 2014
ER  - 
TY  - JOUR
LB  - 149.
AU  - Katz, JA
TI  - Postoperative endoscopic surveillance in Crohn’s disease: bottom up or top down?
J2  - Gastrointest Endosc
PY  - 2007
VL  - 66
SP  - 541
EP  - 543
UR  - https://doi.org/10.1016/j.gie.2007.02.060
ER  - 
TY  - ELEC
LB  - 150.
AU  - Kuznar, W
AU  - Writer, M
TI  - Step-up therapy program for anti-inflammatory biologic agents does not increase cost nor adversely affect patient outcomes
UR  - https://ahdbonline.com/issues/2013/may-june-2013-vol-6-no-4/1419-article-1419
M1  - June 2019
ER  - 
TY  - JOUR
LB  - 151.
AU  - Lee, J
AU  - Biasci, D
AU  - Noor, N
AU  - McKinney, E
AU  - Ahmad, T
AU  - Lewis, N
TI  - PROFILE trial: predicting outcomes for Crohn’s disease using a molecular biomarker
J2  - J Crohns Colitis
PY  - 2017
VL  - 11
SP  - S55
UR  - https://doi.org/10.1093/ecco-jcc/jjx002.085
ER  - 
TY  - JOUR
LB  - 152.
AU  - Meier, J
AU  - Sturm, A
TI  - Top-down versus step-up: new strategies in the treatment of Crohn’s disease
J2  - Z Gastroenterol
PY  - 2009
VL  - 47
SP  - 240
EP  - 242
UR  - https://doi.org/10.1055/s-0028-1109073
ER  - 
TY  - JOUR
LB  - 153.
AU  - Peyrin-Biroulet, L
AU  - Bigard, MA
AU  - Malesci, A
AU  - Danese, S
TI  - Step-up and top-down approaches to the treatment of Crohn’s disease: early may already be too late
J2  - Gastroenterology
PY  - 2008
VL  - 135
SP  - 1420
EP  - 1422
UR  - https://doi.org/10.1053/j.gastro.2008.08.017
ER  - 
TY  - JOUR
LB  - 154.
AU  - Sucong, L
AU  - Baili, C
AU  - Yinglian, X
AU  - Kang, C
AU  - Yao, H
AU  - Zhirong, Z
TI  - Endoscopic and clinical follow-up of step-up and top-down infliximab therapy in Crohn’s disease
J2  - J Gastroenterol Hepatol
PY  - 2013
VL  - 28
SP  - 369
ER  - 
TY  - ELEC
LB  - 155.
AU  - Xiao, Y
AU  - Chen, B
AU  - He, Y
AU  - Gao, X
AU  - Huang, M
AU  - Hu, P
TI  - The Clinical and Endoscopic Efficacy of Step-up and Top-down Infliximab Therapy in Crohn’s Disease
PY  - 2012
UR  - www.cochranelibrary.com/central/doi/10.1002/central/CN-00914623/full
M1  - 2019
ER  - 
TY  - JOUR
LB  - 156.
AU  - Colombel, JF
AU  - Sandborn, WJ
AU  - Rutgeerts, P
AU  - Enns, R
AU  - Hanauer, SB
AU  - Panaccione, R
TI  - Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial
J2  - Gastroenterology
PY  - 2007
VL  - 132
SP  - 52
EP  - 65
UR  - https://doi.org/10.1053/j.gastro.2006.11.041
ER  - 
TY  - JOUR
LB  - 157.
AU  - Sandborn, WJ
AU  - Hanauer, SB
AU  - Rutgeerts, P
AU  - Fedorak, RN
AU  - Lukas, M
AU  - MacIntosh, DG
TI  - Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial
J2  - Gut
PY  - 2007
VL  - 56
SP  - 1232
EP  - 1239
UR  - https://doi.org/10.1136/gut.2006.106781
ER  - 
TY  - JOUR
LB  - 158.
AU  - Rutgeerts, P
AU  - Van Assche, G
AU  - Sandborn, WJ
AU  - Wolf, DC
AU  - Geboes, K
AU  - Colombel, JF
TI  - Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial
J2  - Gastroenterology
PY  - 2012
VL  - 142
SP  - 1102
EP  - 11.e2
UR  - https://doi.org/10.1053/j.gastro.2012.01.035
ER  - 
TY  - JOUR
LB  - 159.
AU  - Sandborn, WJ
AU  - Rutgeerts, P
AU  - Enns, R
AU  - Hanauer, SB
AU  - Colombel, JF
AU  - Panaccione, R
TI  - Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial
J2  - Ann Intern Med
PY  - 2007
VL  - 146
SP  - 829
EP  - 838
UR  - https://doi.org/10.7326/0003-4819-146-12-200706190-00159
ER  - 
TY  - JOUR
LB  - 160.
AU  - Targan, SR
AU  - Hanauer, SB
AU  - van Deventer, SJ
AU  - Mayer, L
AU  - Present, DH
AU  - Braakman, T
TI  - A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group
J2  - N Engl J Med
PY  - 1997
VL  - 337
SP  - 1029
EP  - 1035
UR  - https://doi.org/10.1056/NEJM199710093371502
ER  - 
TY  - ELEC
LB  - 161.
AU  - National Institute for Health and Care Excellence (NICE)
TI  - Briefing Paper for Methods Review Working Party on Companion Diagnostics
PY  - 2011
UR  - http://nicedsu.org.uk/wp-content/uploads/2016/03/DSU_TAMethodsGuideReviewSupportingDocuments.pdf
M1  - 26 January 2021
ER  -